OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Review of Vaccines is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?	99
Indirect protection from rotavirus vaccines: a systematic review	91
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response	77
Parental category B vaccine hesitancy and associated factors in China: an online cross-sectional survey	71
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States	69
Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China	62
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant	60
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy	54
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic	52
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China	50
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis	47
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children	44
Personal and contextual determinants of COVID-19 vaccination intention: a vignette study	42
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumo	42
Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness	41
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis	41
Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus	41
Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China	41
Effectiveness of maternal vaccination with quadrivalent inactivated influenza vaccine in pregnant women and their infants in 2019-2020	39
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era	37
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom	36
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review	36
Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany	36
The important lessons lurking in the history of meningococcal epidemiology	35
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection	35

Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays	35
Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women	34
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above	34
Microarray patches: scratching the surface of vaccine delivery	34
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond	34
Who is more likely to hesitate to accept COVID-19 vaccine: a cross-sectional survey in China	33
Vaccines against leishmaniasis: using controlled human infection models to accelerate development	32
Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy	32